JP2024506228A - 脂質関連障害の処置のための組成物および方法 - Google Patents

脂質関連障害の処置のための組成物および方法 Download PDF

Info

Publication number
JP2024506228A
JP2024506228A JP2023517276A JP2023517276A JP2024506228A JP 2024506228 A JP2024506228 A JP 2024506228A JP 2023517276 A JP2023517276 A JP 2023517276A JP 2023517276 A JP2023517276 A JP 2023517276A JP 2024506228 A JP2024506228 A JP 2024506228A
Authority
JP
Japan
Prior art keywords
acid
formula
compound
pharmaceutical composition
milligrams
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023517276A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024506228A5 (cg-RX-API-DMAC7.html
Inventor
ブローグランド,エラン
ブルメンフェルド,アロン
ヴェレッド,シャロン コーエン
ゲータ,ラケーリ
Original Assignee
ラジエル セラピューティクス エルティーディー.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ラジエル セラピューティクス エルティーディー. filed Critical ラジエル セラピューティクス エルティーディー.
Publication of JP2024506228A publication Critical patent/JP2024506228A/ja
Publication of JP2024506228A5 publication Critical patent/JP2024506228A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/203—Retinoic acids ; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2023517276A 2020-09-16 2021-09-15 脂質関連障害の処置のための組成物および方法 Pending JP2024506228A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063079195P 2020-09-16 2020-09-16
PCT/IB2021/000640 WO2022058795A1 (en) 2020-09-16 2021-09-15 Compositions and methods for the treatment of lipid-related disorders

Publications (2)

Publication Number Publication Date
JP2024506228A true JP2024506228A (ja) 2024-02-13
JP2024506228A5 JP2024506228A5 (cg-RX-API-DMAC7.html) 2024-09-25

Family

ID=80776673

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023517276A Pending JP2024506228A (ja) 2020-09-16 2021-09-15 脂質関連障害の処置のための組成物および方法

Country Status (7)

Country Link
US (1) US20230355584A1 (cg-RX-API-DMAC7.html)
EP (1) EP4213835A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024506228A (cg-RX-API-DMAC7.html)
CN (1) CN116685316A (cg-RX-API-DMAC7.html)
AU (1) AU2021344871A1 (cg-RX-API-DMAC7.html)
IL (1) IL301325A (cg-RX-API-DMAC7.html)
WO (1) WO2022058795A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016203468A1 (en) 2015-06-15 2016-12-22 Raziel Therapeutics Ltd. Carbazole derivatives for the treatment of fibrotic diseases and related symptoms, and conditions thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014533264A (ja) * 2011-11-15 2014-12-11 イッサム リサーチ デベロップメント カンパニー オブ ザ ヘブリュー ユニバーシティー オブ エルサレム リミテッド 三環式化合物、それらを含む組成物およびそれらの使用
WO2016020919A1 (en) * 2014-08-07 2016-02-11 Raziel Therapeutics Ltd. Compositions comprising tricyclic compounds, and uses thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014533264A (ja) * 2011-11-15 2014-12-11 イッサム リサーチ デベロップメント カンパニー オブ ザ ヘブリュー ユニバーシティー オブ エルサレム リミテッド 三環式化合物、それらを含む組成物およびそれらの使用
WO2016020919A1 (en) * 2014-08-07 2016-02-11 Raziel Therapeutics Ltd. Compositions comprising tricyclic compounds, and uses thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ABHAY TALATHI ET AL.: "Fat busters: Lipolysis for face and neck", JOURNAL OF CUTANEOUS AND AESTHETIC SURGERY, vol. 11, no. 2, JPN6025045793, 2018, pages 67, ISSN: 0005726648 *
SHAMBAN, AVA T.: "Noninvasive Submental Fat Compartment Treatment", PLASTIC AND RECONSTRUCTIVE SURGERY GLOBAL OPEN, vol. Vol.4, Issue 12S, JPN6026032813, December 2016 (2016-12-01), pages 1155 - 1, ISSN: 0005925466 *

Also Published As

Publication number Publication date
AU2021344871A9 (en) 2024-08-08
CN116685316A (zh) 2023-09-01
AU2021344871A1 (en) 2023-05-25
WO2022058795A1 (en) 2022-03-24
US20230355584A1 (en) 2023-11-09
IL301325A (en) 2023-05-01
EP4213835A1 (en) 2023-07-26
EP4213835A4 (en) 2024-10-02

Similar Documents

Publication Publication Date Title
JP7850665B2 (ja) 血管脂肪腫の処置のための組成物
WO2001078704A2 (en) Gaba substrate and the use thereof for treating cognitive and emotional disorders
JP7822308B2 (ja) 固形腫瘍の処置のための組成物
KR20140099492A (ko) 삼환식 화합물, 이를 포함하는 조성물 및 그의 용도
AU2020383537A1 (en) Combination of a BTK inhibitor and an MDM2 inhibitor for cancer treatment
IE922181A1 (en) The use of sulphur-containing carboxylic acids to combat¹physiologically-induced excitatory disorders and diseases¹related thereto as well as allergic diseases and also the¹preparation of corresponding medicaments
KR20170141774A (ko) 항바이러스 및 항염증 치료제의 치료 조합물
US20230355584A1 (en) Compositions and methods for the treatment of lipid-related disorders
CA2920073A1 (en) Boosting the effect of methotrexate through the combined use with lipophilic statins
CN109562097B (zh) 穿心莲内酯治疗多发性硬化的进行形式
WO2022058792A1 (en) Compositions for the treatment of fat related conditions and disorders
US20240335424A1 (en) Compositions and methods for treating lipoma pain
RU2358723C1 (ru) Средство, обладающее антипохмельным действием, биологически активная добавка, фармацевтическая композиция, лекарственное средство и способ получения
HK40077772A (en) Compositions for the treatment of solid tumors
RU2404976C1 (ru) Средство, снижающее влечение к алкоголизму, фармацевтическая композиция, способ ее получения, лекарственное средство и способ лечения
US20200289593A1 (en) Spirulina carotenoid complex
RU2719376C1 (ru) Лекарственное средство седативного и миорелаксантного действия
WO2023220768A1 (en) Acne control formulations
WO2012058993A1 (zh) 安倍生坦预防或减轻缺氧导致的心功能损伤的用途
UA68126A (en) Method for correcting homeostasis upon radiation exposure

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230405

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240913

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240913

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251110

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260209

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260409

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260511

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260805